Mutations in ERBB4 may have a minor role in melanoma pathogenesis

Journal of Investigative Dermatology

Volumn 133, Issue 6, 2013, Pages 1685-1687

  Manca, Antonella ^a   Lissia, Amelia ^b   Cossu, Antonio ^b   Rubino, Corrado ^c   Ascierto, Paolo A ^d   Stanganelli, Ignazio ^e   Palmieri, Giuseppe ^a  

^a CNR   (Italy)

^b UNIVERSITY HOSPITAL OF SASSARI   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e Romagna Tumor Institute   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GENOMIC DNA; PROTEIN TYROSINE KINASE;

CANCER PATIENT; CUTANEOUS MELANOMA; GENE SEQUENCE; HUMAN; LETTER; MELANOMA; MELANOMA CELL; METASTASIS; MUTATION; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SOMATIC MUTATION;

EID: 84878555480     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.27     Document Type: Letter

References (15)

1. Ascierto PA, Grimaldi AM, Curti B et al. (2012) Future Perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med 10:83
2. Carrasco-García E, Saceda M, Grasso S et al. (2011) Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. Exp Cell Res 317:1476-89
3. Casula C, Muggiano A, Cossu A et al. (2009) Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. BMC Cancer 9:352
4. Dutton-Regester K, Irwin D, Hunt P et al. (2012) A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. Mol Cancer Ther 11:888-97
5. Easty DJ, Gray SG, O'Byrne KJ et al. (2011) Receptor tyrosine kinases and their activation in melanoma. Pigment Cell Melanoma Res 24:446-61
6. Flaherty KT, Hodi FS, Fisher DE (2012) From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12:349-61
7. Hodis E, Watson IR, Kryukov GV et al. (2012) A landscape of driver mutations in melanoma. Cell 150:251-63
8. Krauthammer M, Kong Y, Ha BH et al. (2012) Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 44:1006-14
9. Palmieri G, Capone ME, Ascierto ML et al. (2009) Main roads to melanoma. J Transl Med 7:86
10. Palomba G, Colombino M, Contu A et al. (2012) Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. J Transl Med 10:178
11. Pharoah PDP (2009) Shedding light on skin cancer. Nat Genet 40:817-8
12. Prickett TD, Agrawal NS, Wei X et al. (2009) Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 41:1127-32
13. Rudloff U, Samuels Y (2010) A growing family: adding mutated Erbb4 as a novel cancer target. Cell Cycle 9:1487-503
14. Settleman J (2009) A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin. Cancer Cell 16:278-9
15. Tsao H, Chin L, Garraway LA et al. (2012) Melanoma: from mutations to medicine. Genes Dev 26:1131-55